$14.845
+0.17
(+1.12%)▲
Insights on Certara Inc
Revenue is down for the last 2 quarters, 90.45M → 85.57M (in $), with an average decrease of 5.4% per quarter
Netprofit is down for the last 2 quarters, 4.70M → -48.96M (in $), with an average decrease of 1140.5% per quarter
In the last 1 year, 10x Genomics Inc has given 23.0% return, outperforming this stock by 29.9%
1.01%
Downside
Day's Volatility :2.39%
Upside
1.39%
20.47%
Downside
52 Weeks Volatility :52.68%
Upside
40.5%
Period | Certara Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -7.79% | -2.6% | 0.0% |
6 Months | -31.56% | 2.2% | 0.0% |
1 Year | -6.91% | -4.3% | -3.4% |
3 Years | -61.45% | 19.1% | -4.7% |
Market Capitalization | 2.4B |
Book Value | $6.58 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.22 |
Wall Street Target Price | 17.14 |
Profit Margin | -9.56% |
Operating Margin TTM | -6.78% |
Return On Assets TTM | 1.17% |
Return On Equity TTM | -3.2% |
Revenue TTM | 353.0M |
Revenue Per Share TTM | 2.23 |
Quarterly Revenue Growth YOY | 1.0% |
Gross Profit TTM | 203.1M |
EBITDA | 82.7M |
Diluted Eps TTM | -0.22 |
Quarterly Earnings Growth YOY | -0.14 |
EPS Estimate Current Year | 0.45 |
EPS Estimate Next Year | 0.48 |
EPS Estimate Current Quarter | 0.11 |
EPS Estimate Next Quarter | 0.11 |
What analysts predicted
Upside of 15.46%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 163.7M | - |
Net Income | -33.3M | - |
Net Profit Margin | -20.31% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 208.5M | ↑ 27.36% |
Net Income | -8.9M | ↓ 73.16% |
Net Profit Margin | -4.28% | ↑ 16.03% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 243.5M | ↑ 16.79% |
Net Income | -49.4M | ↑ 453.41% |
Net Profit Margin | -20.28% | ↓ 16.0% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 286.1M | ↑ 17.48% |
Net Income | -13.3M | ↓ 73.14% |
Net Profit Margin | -4.64% | ↑ 15.64% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 335.6M | ↑ 17.32% |
Net Income | 14.7M | ↓ 211.04% |
Net Profit Margin | 4.39% | ↑ 9.03% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 82.8M | ↑ 1.48% |
Net Income | -589.0K | ↓ 126.65% |
Net Profit Margin | -0.71% | ↓ 3.42% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 84.7M | ↑ 2.34% |
Net Income | 3.9M | ↓ 768.25% |
Net Profit Margin | 4.65% | ↑ 5.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 86.6M | ↑ 2.28% |
Net Income | 9.2M | ↑ 133.08% |
Net Profit Margin | 10.59% | ↑ 5.94% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 90.3M | ↑ 4.23% |
Net Income | 1.4M | ↓ 85.2% |
Net Profit Margin | 1.5% | ↓ 9.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 90.5M | ↑ 0.17% |
Net Income | 4.7M | ↑ 246.54% |
Net Profit Margin | 5.2% | ↑ 3.7% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 85.6M | ↓ 5.39% |
Net Income | -49.0M | ↓ 1140.48% |
Net Profit Margin | -57.22% | ↓ 62.42% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | - |
Total Liabilities | 558.7M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↓ 1.37% |
Total Liabilities | 545.0M | ↓ 2.45% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 22.4% |
Total Liabilities | 447.3M | ↓ 17.94% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 19.09% |
Total Liabilities | 469.9M | ↑ 5.06% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 4.05% |
Total Liabilities | 493.3M | ↑ 4.98% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 0.35% |
Total Liabilities | 453.4M | ↓ 1.15% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↑ 0.46% |
Total Liabilities | 454.3M | ↑ 0.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 4.26% |
Total Liabilities | 493.3M | ↑ 8.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↓ 0.39% |
Total Liabilities | 481.7M | ↓ 2.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↑ 0.35% |
Total Liabilities | 475.0M | ↓ 1.38% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.5B | ↓ 2.89% |
Total Liabilities | 475.1M | ↑ 0.01% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.6M | - |
Investing Cash Flow | -73.9M | - |
Financing Cash Flow | 57.3M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 38.0M | ↑ 228.03% |
Investing Cash Flow | -9.5M | ↓ 87.12% |
Financing Cash Flow | -8.5M | ↓ 114.82% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 44.8M | ↑ 17.84% |
Investing Cash Flow | -8.6M | ↓ 9.51% |
Financing Cash Flow | 208.2M | ↓ 2552.75% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 60.4M | ↑ 34.76% |
Investing Cash Flow | -269.9M | ↑ 3034.25% |
Financing Cash Flow | 123.4M | ↓ 40.74% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 92.5M | ↑ 53.25% |
Investing Cash Flow | -27.8M | ↓ 89.69% |
Financing Cash Flow | -7.4M | ↓ 105.97% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 23.3M | ↑ 137.26% |
Investing Cash Flow | -3.2M | ↓ 62.68% |
Financing Cash Flow | -3.5M | ↑ 132.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 24.0M | ↑ 3.17% |
Investing Cash Flow | -3.3M | ↑ 2.66% |
Financing Cash Flow | -1.3M | ↓ 61.94% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 35.5M | ↑ 47.88% |
Investing Cash Flow | -12.6M | ↑ 279.03% |
Financing Cash Flow | -968.0K | ↓ 27.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 10.0M | ↓ 71.94% |
Investing Cash Flow | -2.7M | ↓ 78.32% |
Financing Cash Flow | -850.0K | ↓ 12.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 18.1M | ↑ 81.36% |
Investing Cash Flow | -11.7M | ↑ 329.55% |
Financing Cash Flow | -6.4M | ↑ 655.29% |
Sell
Neutral
Buy
Certara Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Certara Inc | 21.12% | -31.56% | -6.91% | -61.45% | -61.45% |
![]() 10x Genomics Inc | 19.47% | -21.02% | 23.01% | -72.11% | -19.03% |
![]() Veeva Systems Inc. | -8.91% | 5.91% | -7.15% | -37.4% | 77.25% |
![]() Ge Healthcare Technologies Inc. | 12.62% | -8.75% | 17.61% | 17.61% | 17.61% |
![]() Healthequity Inc | -7.46% | 21.42% | 7.55% | -6.37% | -21.13% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Certara Inc | 100.92 | NA | NA | 0.45 | -0.03 | 0.01 | 0.0 | 6.58 |
![]() 10x Genomics Inc | NA | NA | NA | -2.12 | -0.29 | -0.12 | 0.0 | 6.31 |
![]() Veeva Systems Inc. | 53.83 | 53.83 | 1.27 | 4.18 | 0.15 | 0.05 | 0.0 | 25.85 |
![]() Ge Healthcare Technologies Inc. | 21.77 | 21.77 | NA | 3.82 | 0.15 | 0.06 | 0.0 | 15.67 |
![]() Healthequity Inc | 451.07 | 451.07 | 1.92 | 1.33 | 0.01 | 0.02 | 0.0 | 22.77 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Certara Inc | Buy | $2.4B | -61.45% | 100.92 | -9.56% |
![]() 10x Genomics Inc | Buy | $5.1B | -19.03% | NA | -37.79% |
![]() Veeva Systems Inc. | Buy | $28.7B | 77.25% | 53.83 | 24.2% |
![]() Ge Healthcare Technologies Inc. | Buy | $33.4B | 17.61% | 21.77 | 8.91% |
![]() Healthequity Inc | Buy | $5.8B | -21.13% | 451.07 | 1.37% |
BlackRock Inc
Vanguard Group Inc
Baillie Gifford & Co Limited.
William Blair Investment Management, LLC
ClearBridge Advisors, LLC
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.
Organization | Certara Inc |
Employees | 1150 |
CEO | Dr. William F. Feehery Ph.D. |
Industry | Healthcare |